A Promising Drug Target: NBDY, a Non-Annotated P-Body Dissociating Polypeptide as a Potential therapeutic Approach

Target Name: NBDY

NCBI ID: G550643

NBDY

A Promising Drug Target: NBDY, a Non-Annotated P-Body Dissociating Polypeptide as a Potential therapeutic Approach

Non-Annotated P-Body Dissociating Polypeptide (NBDY) is a 21-kDa protein that is expressed in various tissues of the human body, including brain, heart, and liver. NBDY is involved in various cellular processes, including cell adhesion, migration, and invasion. It has also been implicated in neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Therefore, targeting NBDY as a drug or biomarker holds great potential for the development of new therapeutic approaches.

Drug Target Potential

NBDY has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. One of the key features of NBDY is its P-body dissociating properties, which allow it to interact with various proteins and play a role in protein-protein interactions. This feature makes NBDY an attractive target for small molecules, as they can modulate its stability and activity.

In addition, NBDY has been shown to play a role in various signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, differentiation, and survival, and is a key target for many diseases, including cancer. Therefore, modulating NBDY activity could be a promising approach for the development of new anti-cancer drugs.

Biomarker Potential

NBDY has also been identified as a potential biomarker for several diseases, including neurodegenerative diseases. Its involvement in these diseases makes it an attractive target for diagnostic tools and potential therapeutic approaches.

In Alzheimer's disease, NBDY has been shown to be decreased in the brain, which is consistent with the hypothesis that NBDY plays a role in the development and progression of the disease. Therefore, targeting NBDY with drugs or other therapeutic approaches could be a promising approach for the treatment of Alzheimer's disease.

In Parkinson's disease, NBDY has been shown to be involved in the neurodegeneration that occurs in the disease. Therefore, targeting NBDY with drugs or other therapeutic approaches could be a promising approach for the treatment of Parkinson's disease.

Conclusion

In conclusion, NBDY is a non-annotated protein that has been shown to play a role in various cellular processes and signaling pathways. Its P-body dissociating properties and its involvement in neurodegenerative diseases make it an attractive target for small molecules and potential therapeutic approaches. Additionally, NBDY has also been identified as a potential biomarker for several diseases, including neurodegenerative diseases. Therefore, future studies will be focused on modulating NBDY activity and its potential use as a drug or biomarker.

Protein Name: Negative Regulator Of P-body Association

Functions: Promotes dispersal of P-body components and is likely to play a role in the mRNA decapping process

The "NBDY Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NBDY comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets